Poseida Therapeutics Inc. (NASDAQ:PSTX) finished Friday with an addition of $0.07 to close at $5.30, an upside of 1.34 percent. An average of 424,800 shares of common stock have been traded in the last five days. There was a gain of $0.16 in the past week, and it reached a new high 2 times over the past 12 months. The last 20 days have seen an average of 562,860 shares traded, while the 50-day average volume stands at 476,540.
PSTX stock has increased by 16.23% in the last month. The company shares reached their 1-month lowest point of $4.43 on 12/02/22. With the stock rallying to its 52-week high on 01/04/22, shares of the company touched a low of $1.82 and a high of $7.25 in 52 weeks. It has reached a new high 2 times so far this year and lost -22.17% or -$1.51 in price. In spite of this, the price is down -26.90% from the 52-week high.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
PSTX stock investors should be aware that Poseida Therapeutics Inc. (PSTX) stock had its last reported insider trading activity 150 days ago on Aug 08.
Poseida Therapeutics Inc. (PSTX) has a trailing price-to-sales (P/S) ratio at 3.01, the price-to-book (PB) ratio at 1.87.
The quick ratio of Poseida Therapeutics Inc. for the three months ended June 29 was 6.60, and the current ratio was 6.60, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.27 and a total debt to equity ratio of 0.00 for the quarter ending June 29. Its gross profit as reported stood at $31.24 million compared to revenue of $31.24 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Poseida Therapeutics Inc.’s return on assets was -10.60%.
For the three-month period that ended June 29, Poseida Therapeutics Inc. had $114.18 million in cash and short-term investments compared to $58.16 million in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of $70.41 million in the quarter, while revenues were grew 164.92%. The analyst consensus anticipated Poseida Therapeutics Inc.’s latest quarter earnings to come in at -$0.76 per share, but it turned out to be -$0.69, a 9.20% surprise. For the quarter, EBITDA amounted to $72.98 million. Shareholders own equity worth $85.95 million.
From a technical analysis perspective, let’s take a brief look at Poseida Therapeutics Inc. (PSTX) price momentum. RSI 9-day as of the close on 30 December was 52.31%, suggesting the stock is Neutral, with historical volatility in this time frame at 134.16%.
As of today, PSTX’s price is $5.13 +3.11% or $0.16 from its 5-day moving average. PSTX is currently trading +11.11% higher than its 20-day SMA and +45.60% higher than its 100-day SMA. However, the stock’s current price level is +25.89% above the SMA50 and +33.17% above the SMA200.
The stochastic %K and %D were 27.51% and 21.47%, respectively, and the average true range (ATR) was 0.40. With the 14-day stochastic at 33.14% and the average true range at 0.41, the RSI (14) stands at 53.59%. The stock has reached 0.04 on the 9-day MACD Oscillator while the 14-day reading was at -0.23.
Cantor Fitzgerald launched coverage on Poseida Therapeutics Inc. (NASDAQ: PSTX) in its analyst report released on January 07, 2022. The firm assigned the stock an Overweight rating. The consensus rating for Poseida Therapeutics Inc. (PSTX) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell PSTX, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 5 others rate it as a “buy”.
What is PSTX’s price target for the next 12 months?
Analysts predict a range of price targets between $10.00 and $24.00, with a median target of $12.50. Taking a look at these predictions, the average price target given by analysts for Poseida Therapeutics Inc. (PSTX) stock is $14.75.